Skip to main content


Latest articles

19-06-2019 | Diabetes | News | Article

DiRECT: Beta cells ‘not dead’ in type 2 diabetes

People who achieved sustained remission of type 2 diabetes via substantial weight loss in the DiRECT trial regained normal maximal beta-cell capacity, the investigators report.

19-06-2019 | Diabetes | News | Article

First trimester high-volume exercise may reduce gestational diabetes risk

A high volume of moderate-to-vigorous intensity exercise during the first trimester of pregnancy may reduce the risk for hyperglycemia and gestational diabetes later on, research shows.

18-06-2019 | Diabetes | News | Article

High-intensity exercise may trigger hypoglycemia counterregulatory response

Research presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, suggests that high-intensity exercise can partially restore counterregulatory responses to hypoglycemia in people with impaired awareness of the condition.

18-06-2019 | Diabetes | News | Article

Hyperglycemia may impact brain development in children with type 1 diabetes

Researchers report that having type 1 diabetes may affect children’s brain growth and cognitive development, with persistent hyperglycemia the most likely culprit.

14-06-2019 | Diabetes | News | Article

Teplizumab, low-dose ATG hold greatest type 1 diabetes immunotherapy promise

Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.

13-06-2019 | Diabetes | News | Article

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

11-06-2019 | Diabetes | News | Article

CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

10-06-2019 | Diabetes | News | Article

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

10-06-2019 | Diabetes | News | Article

RISE adult medication results highlight disparity with youth with diabetes

10-06-2019 | Diabetes | News | Article

PIONEER 8: Semaglutide add-on lowers HbA1c in type 2 diabetes insulin users

Oral semaglutide significantly reduces glycated hemoglobin and bodyweight versus placebo in people with type 2 diabetes that is poorly controlled on insulin, results of the PIONEER 8 study show.

09-06-2019 | Diabetes | News | Article

Teplizumab delays onset of overt type 1 diabetes

Phase II findings show that the immunotherapy teplizumab significantly prolongs the time until people at very high risk for developing type 1 diabetes are diagnosed with the condition.

09-06-2019 | Diabetes | News | Article

PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing

The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.

09-06-2019 | Diabetes | News | Article

IDegLira delays need for treatment intensification over glargine

Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.

09-06-2019 | Diabetes | News | Article

TODAY2 confirms steep type 2 diabetes trajectory in youth

The latest analysis from the observational follow-up of the TODAY study participants shows rapid accumulation of cardiovascular risk factors and diabetes complications in people who were diagnosed with type 2 diabetes in youth.

09-06-2019 | Diabetes | News | Article

PIONEER 2, PIONEER 4 show benefits of oral semaglutide in type 2 diabetes

Data from the phase IIIa PIONEER 2 and PIONEER 4 studies show that semaglutide equals or betters both empagliflozin and liraglutide for the reduction of glycated hemoglobin in patients with type 2 diabetes uncontrolled on metformin.

08-06-2019 | Diabetes | News | Article

No evidence for Vitamin D in type 2 diabetes prevention

High-dose vitamin D supplementation does not significantly reduce the risk for developing type 2 diabetes among people with prediabetes, show D2d trial data.

06-06-2019 | Diabetes | News | Article

Liraglutide may be an option for people with unresolved type 2 diabetes after metabolic surgery

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

05-06-2019 | Diabetes | News | Article

Hybrid immune cell could contribute to type 1 diabetes autoimmunity

Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.

04-06-2019 | Diabetes | News | Article

Depressive symptoms linked to DKA risk in type 1 diabetes

People with type 1 diabetes who have depressive symptoms may have an increased risk for diabetic ketoacidosis as well as deteriorating glycemic control, research suggests.

03-06-2019 | Diabetes | News | Article

Extended behavioral intervention suggested for optimal glycemic control

Obese adults with prediabetes may need a longer-than-recommended course of behavioral weight loss treatment to optimize improvements in glycemic control, US researchers report.